42 U.S.C. § 1320a-7i — Reporting of information relating to drug samples
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
(a) In general Not later than April 1 of each year (beginning with 2012), each manufacturer and authorized distributor of record of an applicable drug shall submit to the Secretary (in a form and manner specified by the Secretary) the following information with respect to the preceding year: (1) In the case of a manufacturer or authorized distributor of record which makes distributions by mail or common carrier under subsection (d)(2) of section 353 of title 21 , the identity and quantity of drug samples requested and the identity and quantity of drug samples distributed under such subsection during that year, aggregated by— (A) the name, address, professional designation, and signature of the practitioner making the request under subparagraph (A)(i) of such subsection, or of any individual who makes or signs for the request on behalf of the practitioner; and (B) any other category of information determined appropriate by the Secretary . (2) In the case of a manufacturer or authorized distributor of record which makes distributions by means other than mail or common carrier under subsection (d)(3) of such section 353 of title 21 , the identity and quantity of drug samples requested and the identity and quantity of drug samples distributed under such subsection during that year, aggregated by— (A) the name, address, professional designation, and signature of the practitioner making the request under subparagraph (A)(i) of such subsection, or of any individual who makes or signs for the request on behalf of the practitioner; and (B) any other category of information determined appropriate by the Secretary . (b) Definitions In this section: (1) Applicable drug The term “ applicable drug ” means a drug— (A) which is subject to subsection (b) of such section 353 of title 21 ; and (B) for which payment is available under subchapter XVIII or a State plan under subchapter XIX or XXI (or a waiver of such a plan). (2) Authorized distributor of record The term “ authorized distributor of record ” has the meaning given that term in subsection (e)(3)(A) of such section. (3) Manufacturer The term “ manufacturer ” has the meaning given that term for purposes of subsection (d) of such section. (Aug. 14, 1935, ch. 531, title XI, § 1128H, as added Pub. L. 111–148, title VI, § 6004 , Mar. 23, 2010 , 124 Stat. 697 .)
Related documents
- 21 U.S.C. § 1505a — Annual report on development and deployment of narcotics detection technologies#576938
- 21 U.S.C. § 379r — National uniformity for nonprescription drugs#577246
- 21 U.S.C. § 862b — Sanctioning for testing positive for controlled substances#577076
- 25 U.S.C. § 1680q — Prescription drug monitoring#582382
- 21 U.S.C. § 356 — Expedited approval of drugs for serious or life-threatening diseases or conditions#577372
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive